| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | NSC-207895 | GDSC1000 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.064 | 0.2 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | -0.099 | 0.2 |
| mRNA | AICAR | GDSC1000 | pan-cancer | AAC | -0.041 | 0.2 |
| mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | -0.098 | 0.2 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |